JP5457042B2 - Transdermal drug delivery system - Google Patents

Description

  The present invention relates to a patch having a transdermal drug and a transdermal drug administration system that administers a drug from the skin by applying an electric current to the patch attached to the skin using a predetermined controller.

  In general, oral administration or administration by injection is often used for administration of drugs. In the case of oral administration, there is a problem that water-soluble drugs and polymer drugs are not sufficiently absorbed, although they are easy to take and safe. In the case of injection, there is an advantage that it is fast-acting, but there is a disadvantage that it causes pain to the patient.

  At present, the development of a drug administration system through the skin (hereinafter referred to as a transdermal drug administration system) is underway for the purpose of compensating for the problems and disadvantages of these conventional methods. Several methods have been proposed for transdermal drug delivery systems, such as a method using electrical energy and a method using ultrasound.

  Among the methods using electric energy, iontophoresis is a method that has been studied for a long time and has been put into practical use. Iontophoresis is based on the fact that positive and negative electrodes are attached at two points away from the skin, cross the stratum corneum of the skin from the positive electrode, pass through the inside of the body from the stratum corneum, and generate a current that leads to the negative electrode. In the stratum corneum portion, the charged drug is moved and absorbed by the principle of electrophoresis. In principle, charged drugs are the targets of absorption promotion, but since water flows due to electric current, it has been reported that even drugs without charge or drugs with large molecular weight increase skin permeability.

  In Patent Document 1, as an example of iontophoresis, it is disclosed that a battery-powered controller is combined with a patch including a drug on an electrode, and power is supplied from the controller to the electrode. In Patent Document 1, the type of patch is determined based on the light reflection state on a plurality of reflecting plates provided in the patch, and the supply current to the patch is switched.

  General iontophoresis includes a patch containing a drug and a controller that supplies a current to the patch, and the power source of the controller is supplied from a wall power source. For this reason, there has been a tendency to increase the size of the system including the controller, and further, there has been a problem that the behavior of the patient is restricted even during drug administration.

  In general iontophoresis, a qualified person such as a doctor or nurse can set the electrical output, that is, the energy and energy profile (time-change waveform) according to the patient's symptoms. I went there. Note that the profile in iontophoresis means setting of the drug administration rate, drug administration time, current value, and the like. Since the profile setting operation is a method of adjusting the volume and the like in the controller for each patch, handling a plurality of types of patches is time consuming and difficult to manage and check. Moreover, since it has such a function, the controller is a stationary type and large.

  On the other hand, the controller of Patent Document 1 is small because it simply switches the supply current without setting a complicated profile, and it is battery-driven, so it restrains the patient during drug administration. There is nothing.

Japanese National Patent Publication No. 11-506368

  By the way, in the iontophoresis of the type as described in Patent Document 1, only the supply current is switched according to the patch, and the current value cannot be changed according to time. In addition, there are limits to the types of patches that can be handled due to circuit limitations. The controller battery needs to be replaced, and maintenance is troublesome.

  Further, as in Patent Document 1, in order to directly determine the type of patch by the controller, there is a problem that the controller is increased in size accordingly.

  The present invention has been made in consideration of such problems, and by setting the profile according to the patch automatically and with one controller without restraining the patient who is administering the drug, It is an object of the present invention to provide a small-sized transdermal drug administration system while simplifying management and confirmation.

  A transdermal drug administration system according to the present invention includes a drug in an electrode unit, a plurality of types of patches including an identification information storage unit in which identification information is recorded, and one patch connected to the electrode unit to supply power to the electrode unit. A controller provided with a power storage unit, and a cradle in which the patch and the controller are set, and the cradle is recorded with a plurality of profiles including the administration rate and administration time of the drug according to the type of the patch. A storage unit; a first communication unit that reads the identification information from the patch; and a selection unit that selects one from a plurality of profiles of the storage unit based on the identification information obtained from the first communication unit; A second communication unit for supplying the profile selected by the selection unit to the controller, and the controller is obtained from the second communication unit. It was based on the profile, and wherein varying the current to the electrode portion from the storage unit.

  A transdermal drug administration system according to the present invention includes a drug in an electrode unit, a plurality of types of patches including an identification information storage unit in which identification information is recorded, and one patch connected to the electrode unit to supply power to the electrode unit. A controller including a power storage unit that performs the operation, and a patch and a cradle in which the controller is set. The cradle is obtained from the first communication unit and the first communication unit that reads the identification information from the patch. A second communication unit that supplies identification information to the controller, the controller including a storage unit in which a plurality of profiles including the administration rate and administration time of the drug according to the type of the patch are recorded, and the second A selection unit that selects one of a plurality of profiles in the storage unit based on the identification information obtained from the communication unit, and selected by the selection unit. Based on the profile, and wherein varying the current to the electrode portion from the storage unit.

  This makes it easy to manage and check the current profile according to the patch, without restricting the patient who is administering the drug, and to make the system more compact. It becomes.

  The first communication unit may be a communication unit based on a predetermined first communication method, and the second communication unit may be a communication unit based on a second communication method different from the first communication method.

  By using different communication methods for the first communication method and the second communication method, stable communication can be performed without interfering with each other.

  The identification information storage means may be an RF tag chip, and the first communication method may be RF communication. Further, the RF tag chip may be a passive type.

  By performing RF communication, which is wireless communication, mechanical contact of a connector or the like is not necessary for communication with a patch, and communication failure due to entry of foreign matter or the like can be prevented. Moreover, it is suitable also in terms of product durability. In addition, the patch does not require a power source such as a battery, and the patch can be miniaturized. In addition, since there is no power source, there is no restriction on the storage period of the RF tag, thereby simplifying patch management.

  Furthermore, the second communication method may be infrared communication.

  By performing infrared communication that is wireless communication, mechanical contact of a connector or the like is not necessary for communication with the controller, and communication failure due to entry of foreign matter or the like can be prevented. Moreover, it is suitable also in terms of product durability. Furthermore, by using a different communication method from the first communication method, since the communication position and means (infrared rays and radio waves) are different, stable communication can be performed without interfering with each other.

  The cradle may be capable of charging the power storage unit.

  Thereby, the replacement frequency of the power storage unit of the controller is reduced, and the maintenance becomes simple.

  The identification information storage means may be a barcode. Furthermore, the identification information storage means may be a two-dimensional code. Furthermore, the first communication unit may be a scanner.

  As a result, it is possible to provide an inexpensive system. Since the communication position and means (visible light and infrared light) are different between the first communication method and the second communication method, stable communication can be performed without interference. Can do.

  The profile may further include an initial acceleration time for increasing the administration rate at the start of drug administration.

  Thus, the profile can be set so that the burden on the patient during drug administration is reduced.

  According to the transdermal drug administration system of the present invention, the current profile can be set automatically and with a single controller without restricting the patient who is administering the drug, and with a single controller. In addition, it is possible to achieve the effect that the system can be downsized while the confirmation is simple.

1 is an overall perspective view showing a transdermal drug administration system according to a first embodiment. It is a schematic bottom view of a patch. It is the whole perspective view from the upper direction of a patch. It is a whole perspective view from the downward direction of a controller. It is a schematic block diagram of a controller. It is a correlation diagram of time and current value showing an example of a current profile. 1 is an overall perspective view of a cradle. It is a schematic block diagram of a cradle. It is a flowchart of medicine administration. It is an implementation figure of reading of identification information, and writing of a current profile. It is an implementation figure of medicine administration. It is a disassembled perspective view which shows the transdermal drug administration system which concerns on 2nd Embodiment. It is a whole perspective view from the downward direction of a controller. It is a schematic block diagram of the controller in the transdermal drug administration system concerning a 3rd embodiment. It is a flowchart of medicine administration.

  Hereinafter, the transdermal drug administration system according to the present invention will be described with reference to FIGS.

  As shown in FIG. 1, the transdermal drug administration system 10a according to the first embodiment includes a patch 12, a controller 14a, and a cradle 16 as a basic configuration.

  In the transdermal drug administration system 10a, after the patch 12 is integrated with the controller 14a and attached to the skin of the patient 36, an electric current is passed from the controller 14a to the patch 12 so that the drug 38 provided in the patch 12 is transdermally transmitted. Administer.

  As shown in FIGS. 2 and 3, the patch 12 includes an RF tag chip 20 serving as identification information storage means, a donor reservoir 22, a return reservoir 24, and a pair of connection pins 26a and 26b. The patch 12 has a thin plate shape, and a pair of connection pins 26a and 26b are provided on the upper surface of the patch 12 so as to be directed upward. Here, for the convenience of explanation, the vertical direction in the transdermal drug administration system 10a refers to a direction perpendicular to the contact surface between the patch 12 and the cradle 16 shown in FIG. 1, the controller 14a side being upward, and the cradle 16 side being Is the downward direction, but the actual direction of use is not limited to this. Further, both corners on one short side of the rectangular shape in plan view are chamfered and rounded. Thereby, when connecting with the controller 14a, the direction is not mistaken.

  The RF tag chip 20 is installed at substantially the center of the lower surface of the patch 12. The RF tag chip 20 is a passive RF tag 20a that does not require an external power source such as a battery. The passive RF tag 20a is constituted by an IC chip 30 and an antenna 32. The passive RF tag 20a includes a high-frequency circuit that operates at 800 MHz to 2.54 GHz, a power supply reproduction circuit, a memory control circuit, a memory, and the like (all not shown). The power source of the passive RF tag 20a receives a signal from the outside using a power regeneration circuit and converts it into electric power by regenerating the direct current power. By using the passive RF tag 20a, a power source such as a battery becomes unnecessary, and the patch 12 can be downsized. Further, since there is no power supply, there is no restriction on the storage period of the passive RF tag 20a, and the management of the patch 12 is simplified. Note that the RF tag chip 20 is not limited to the passive RF tag 20a, and may be, for example, an active RF tag.

  Identification information 34 is recorded in the IC chip 30 at the manufacturing stage. By reading the identification information 34 with the cradle 16, the patch 12 can be managed and confirmed.

  The identification information 34 is, for example, 8-bit data, and is information for identifying and confirming the patch 12.

  The antenna 32 is formed on the lower surface of the patch 12 by etching, printing, or the like of aluminum, copper, or silver, and has a function of receiving and reflecting a signal from the controller 14a. The IC chip 30 and the antenna 32 are covered with a film or the like (not shown), so that the IC chip 30 and the antenna 32 are insulated from the outside and do not directly touch the skin of the patient 36.

  On the same surface as the RF tag chip 20, that is, on the lower surface of the patch 12, a donor reservoir 22 and a return reservoir 24 are provided at symmetrical positions from the center. The donor reservoir 22 is filled with the medicine 38 and also has a function as a positive electrode plate. The drug 38 has a cation.

  The return reservoir 24 has the same structure as the donor reservoir 22, but is filled with physiological saline 40 instead of the drug 38, and also has a function as a negative electrode plate. The physiological saline 40 has anions.

  The connection pins 26 a and 26 b are projected from the upper surface of the patch 12 and are connected to the donor reservoir 22 and the return reservoir 24 inside the patch 12. The connection pins 26a and 26b have a function of supplying electricity from the controller 14a to the donor reservoir 22 and the return reservoir 24 by being inserted into the concave connection hooks 42a and 42b in the controller 14a. Further, the pair of connection pins 26a and 26b and the connection hooks 42a and 42b may be provided at asymmetric positions from the center of the respective installation surfaces. Thereby, when connecting the patch 12 and the controller 14a, the direction is not mistaken.

  As shown in FIGS. 1, 4 and 5, the controller 14a has the same shape as the patch 12 in plan view. The controller 14a includes a pair of connection hooks 42a and 42b, a power switch 44, an administration control switch 46, a red light 48a, a green light 48b, a controller communication window 50, a controller power supply 52a, and a controller control unit that is a control circuit for the controller 14a. 54.

  The connecting hooks 42a and 42b are holes arranged in the lower surface of the controller 14a at a size and position that can be engaged with the connecting pins 26a and 26b. The connecting hooks 42a and 42b have a function of energizing between the controller 14a and the patch 12 by engaging with the connecting pins 26a and 26b. The connecting hook 42a is connected to the connecting pin 26a, and the connecting hook 42b is connected to the connecting pin 26b.

  The power switch 44 is turned on so that the controller power supply 52a is energized to the controller control unit 54, thereby enabling communication between the controller 14a and the cradle 16, administration of the medicine 38, and the like. Have As the type of the power switch 44, various types such as an alternate operation type and a momentary operation type are conceivable, but are not limited to any of them. The same applies to each switch described below.

  The administration control switch 46 has a function of administering the medicine 38 into the body of the patient 36 in the on state, and interrupting and terminating the administration of the medicine 38 in the off state. Note that after the administration control switch 46 is turned on and a predetermined time based on a current profile 90 described later has elapsed, it is determined that the administration has ended, and the administration control switch 46 is automatically turned off. It may be set.

  As shown in FIG. 6, the current profile 90 is, for example, 8-bit data indicating the relationship between the time (t) and the current value (I). For example, the administration speed, administration time, and dosage of the drug 38. It is data that prescribes. In the iontophoresis, since the current value is proportional to the administration rate of the drug 38, the dose of the drug 38 can be set simultaneously by setting the current profile 90.

  As shown in FIG. 6, the basic data of the current profile 90 includes initial acceleration time data A for increasing the current value at a constant rate, subsequent current data B, and administration time data C. . For example, if A is set to about 20 to 30 seconds, B is set to about 1 mA, and C is set to about 10 minutes, it is preferable that the patient 36 is not burdened. The initial acceleration time data A, current data B, and administration time data C may be in any expression format as long as the time and current value can be specified. Furthermore, by setting the number of types of the medicine 38 and the current profile 90, the administration speed, administration time, and dosage of the medicine 38 can be easily set. As a result, the patch 12 can be easily managed. be able to.

  The red lamp 48a and the green lamp 48b are display lamps using LEDs (Light Emitting Diodes), for example. The red light 48a has a function of notifying the abnormal operation of the controller 14a to a qualified user 62 such as a patient 36, a doctor, a nurse, or the like by blinking quickly. Further, the red light 48a has a function of notifying the patient 36 or the user 62 that the remaining amount of the controller power source 52a is low by blinking slowly. The green light 48b has a function of notifying the patient 36 and the user 62 that the medicine is being administered normally by blinking. However, the use of the red lamp 48a and the green lamp 48b is not limited to these.

  The controller communication window 50 is a transparent or translucent plastic plate through which infrared light passes when the cradle 16 and the controller control unit 54 perform infrared communication that is the second communication method. In addition, in order to prevent malfunction, the controller communication window 50 may have a function of blocking other than the infrared wavelength peripheral region used for communication.

  The controller power source 52a is a power source having a power storage function such as a dry battery or a button-type battery, and may have any form and size so that the controller 14a can be carried.

  As shown in FIG. 5, the controller control unit 54 includes a CPU (Central Processing Unit) 100 as a main control unit, a controller communication unit 56, an internal memory 58 as a storage unit, a driver 60, and the like. The functional units are realized by the CPU 100 reading a program and executing software processing in cooperation with the controller communication unit 56, the internal memory 58, the driver 60, and the like. As a result of communication with the cradle 16, the controller controller 54 is programmed to execute the current profile 90 received from the cradle 16. In addition, when the drug 38 is administered, if the current based on the current profile 90 is not flowing because the internal resistance of the patient 36 increases or the power supply voltage fluctuates, for example, the controller control unit 54 controls the PID. It also has a function of controlling the administration of the medicine 38 along the current profile 90 by (Proportional Integral Differential) control, PI (Proportional Integral) control, or the like. Thereby, an appropriate electric current can be sent.

  The controller communication unit 56 has a function of performing infrared communication that is the second communication method with the cradle control unit 74 of the cradle 16. Also, it has a function of transmitting the received data to the CPU 100.

  The internal memory 58 includes a nonvolatile memory such as a flash memory, and the current profile 90 received from the cradle 16 is written through the controller communication unit 56 and the CPU 100.

  The driver 60 has a function of supplying current to the connecting hooks 42a and 42b based on the current profile 90 and the control information provided from the controller control unit 54. The driver 60 can freely convert the supply current in terms of time by, for example, a PWM (Pulse Width Modulation) method, and the current supply pattern is not limited on the circuit.

  The controller communication unit 56, the internal memory 58, and the driver 60 may be integrated in the CPU 100.

  As shown in FIG. 7, the cradle 16 has a shape having a cradle body 16a and a cradle wall portion 16b which are substantially rectangular parallelepipeds. Both corners on the side facing the cradle wall 16b having a rectangular shape in plan view are chamfered and rounded. This is the same as the patch 12 and the controller 14a described above, and as a result, as shown in FIG. 1, when the patch 12 and the controller 14a are set together on the cradle body 16a, the user 62 can estimate the direction. It becomes.

  As shown in FIGS. 7 and 8, the cradle 16 includes a power cord 64, a power switch 66, an operation display unit 68, a cradle communication window 70, a set mark 72, and a cradle control unit 74 that is a control circuit for the cradle 16. It is configured. The cradle 16 is supplied with driving power from a wall power supply by a power cord 64 extending from the back surface of the cradle 16, and uses, for example, AC (Alternating Current) 100V or 200V as a power source. Here, an example in which a general commercial wall power source is used is shown, but battery driving may be used.

  The power switch 66 is provided on the side surface of the cradle main body 16a and is energized in an on state, and communication between the patch 12 and the cradle 16 and between the controller 14a and the cradle 16 is possible, and electricity is cut off in an off state. Has the function of

  The operation display unit 68 is, for example, a liquid crystal monitor provided in the cradle body 16a, and has a function of displaying the operation status and communication status of the cradle 16, predetermined error information, operation confirmation, and the like.

  The cradle communication window 70 is a transparent or translucent plastic plate that is provided on the cradle wall 16b and through which infrared rays for infrared communication pass. In order to prevent malfunction, the cradle communication window 70 may have a function of blocking other than the infrared wavelength peripheral region used for communication.

  As shown in FIG. 1, the set mark 72 is a line that serves as a guide for the position when the patch 12 and the controller 14 a are integrally set on the cradle body 16 a. As a result, the controller communication window 50 and the cradle communication window 70 face each other, and a stable communication environment without interference can be secured. The set mark 72 may be a line or groove drawn on the cradle body 16a, and the type, color, or the like such as a solid line or a broken line is not limited. Alternatively, the set mark 72 may be formed as a shallow concave portion, and the patch 12 and the controller 14a may be integrated and shallowly fitted together.

  As shown in FIG. 8, the cradle control unit 74 includes a CPU (Central Processing Unit) 102 as a main control unit, an RF communication unit 110 as a first communication unit, an internal memory 120 as a storage unit, and a second communication unit. The infrared communication unit 200 includes a power source and a driver (not shown). The CPU 102 reads the program, and the RF communication unit 110, the internal memory 120, the infrared communication unit 200, and the driver. This is realized by executing software processing in cooperation with the above.

  The RF communication unit 110 includes an RF transmission / reception unit 112 and an RF antenna 114. The RF communication unit 110 reads the identification information 34 by communicating with the patch 12 by RF (Radio Frequency) communication which is the first communication method. By performing RF communication that is wireless communication, mechanical contact with a connector or the like is not necessary for communication with the patch 12, and communication failure due to entry of foreign matter or the like can be prevented. Moreover, it is suitable also in terms of product durability. Further, the type of the patch 12 is determined by the RF communication unit 110, that is, the cradle 16, so that the controller 14a can be downsized. Note that the first communication method is broad and includes one-sided reading. In addition, as an RF communication method, an electromagnetic coupling method, an electromagnetic induction method, a radio wave method, and the like can be considered, but the method is not limited thereto.

  The RF transmitter / receiver 112 has a function of transmitting a signal to the antenna 32 of the patch 12 via the RF antenna 114 and receiving a reflected wave from the antenna 32. Note that the RF transceiver unit 112 may be integrated in the CPU 102.

  As shown in FIG. 1, when the patch 12 and the controller 14a are integrated and set according to the set mark 72, the RF antenna 114 is preferably disposed in the vicinity of the antenna 32 of the patch 12 (see FIG. 1). 7). As a result, the communication distance is shortened as much as possible, and a stable communication environment without interference can be ensured.

  A plurality of files 152 are recorded in the internal memory 120 as the database 150. Each file 152 includes drug type data 154 that is data of the type of drug 38 corresponding to the type of patch 12, drug filling amount data 156 that is data of the filling amount of the drug 38 filled in the donor reservoir 22, and a current profile. 90 and data such as search identification information 34a for searching the file 152 with the identification information 34 are written. A predetermined selection unit based on the software function of the CPU 102 searches the search identification information 34 a corresponding to the identification information 34 read from the patch 12, thereby selecting an appropriate file 152. Further, the internal memory 120 may be able to update or add to the database 150 by using a non-volatile memory such as a flash memory. The file 152 is data with a small amount of information and can be written in the internal memory 120 in a sufficiently large amount.

  As shown in FIG. 8, the infrared communication unit 200 includes an infrared driver / receiver unit 202, a UART (Universal Asynchronous Receiver Transmitter) 204, a transmission encoder 206, and a reception decoder 208. The infrared communication unit 200 performs infrared communication that is the second communication method with the controller 14a. The infrared communication unit 200 can perform stable communication without interfering with each other by using a communication method of a medium (in this embodiment, infrared rays and radio waves) different from that of the RF communication unit 110. In addition, mechanical contact such as a connector is not required for communication with the controller 14a, and communication failure due to entry of foreign matter or the like can be prevented. Moreover, it is suitable also in terms of product durability.

  The infrared driver / receiver unit 202 may perform communication according to a standard such as IrDA (Infrared Data Association) DATA 1.0 or IrDA DATA 1.1. In other words, all of them are configured by a drive circuit of an infrared LED for transmission (not shown), a photodiode for reception, an amplifier circuit, a noise filter, a comparator, and the like.

  The UART 204 has a function of mutually converting serial transfer type data and parallel transfer type data so that the CPU 102 can communicate with the transmission encoder 206 and the reception decoder 208.

  The transmission encoder 206 has a function of modulating the signal format of the UART 204 into an infrared transmission pulse defined by a standard such as IrDA DATA1.0 and transmitting the pulse to the infrared driver / receiver unit 202.

  Contrary to the transmission encoder 206, the reception decoder 208 has a function of demodulating an infrared reception pulse into a signal format of the UART 204 and transmitting it to the UART 204.

  The UART 204, the transmission encoder 206, and the reception decoder 208 may be integrated in the CPU 102.

  The transdermal drug administration system 10a is basically configured as described above. Next, the administration of the drug 38 performed on the patient 36 using the transdermal drug administration system 10a will be described with reference to FIG. 9 will be used for explanation.

  First, the patch 12, the controller 14a, and the cradle 16 are prepared for the user 62. The donor reservoir 22 of the patch 12 is preliminarily filled with a medicine 38 and the return reservoir 24 is filled with physiological saline 40 at the manufacturing stage. Identification information 34 is recorded in advance on the IC chip 30 of the patch 12 at the manufacturing stage. Further, the cradle 16 has a database 150 written in advance by the manufacturing stage or the user 62.

  In step S1, after the user 62 selects an appropriate patch 12 as shown in FIG. 10, the patch 12 and the controller 14a are integrated by engaging the pair of connecting pins 26 and the connecting hooks 42. And set according to the set mark 72 on the cradle body 16a.

  Next, in step S2, the power switch 44 of the controller 14a and the power switch 66 of the cradle 16 are turned on (see FIGS. 1 and 10).

  In step S3, since the power switch 44 and the power switch 66 are on, a signal is transmitted from the RF antenna 114 of the cradle 16. The signal is converted into electric power via the antenna 32 of the patch 12, and the DC power is regenerated in the patch 12, so that the identification information 34 recorded by the IC chip 30 of the patch 12 is transmitted to the RF communication unit by RF communication. 110. The CPU 102 can check the patch 12 based on the identification information 34. Further, the CPU 102 searches the search identification information 34a corresponding to the identification information 34, selects the file 152 recorded in the database 150 of the internal memory 120, and stores the medicine type data 154, the medicine filling amount data 156, Check the current profile 90 and the like. During the RF communication, the operation display unit 68 may notify the user 62 or the patient 36, for example, by displaying “Communicating”. The operation display unit 68 displays the medicine type data 154 and the medicine filling amount data 156 read from the identification information 34. As a result, the user 62 can easily confirm the medicine 38 to be filled in the patch 12 (step S4), and can prevent the wrong kind of medicine 38 from being administered. When the medicine type data 154 and the medicine filling amount data 156 are not displayed, the process returns to step S2.

  Next, in step S <b> 5, the current profile 90 selected by the CPU 102 is transmitted from the infrared communication unit 200 to the controller control unit 54 of the controller 14 a using infrared communication, and is written in the internal memory 58. At this time, the verification data 92 in a predetermined format together with the current profile 90 is transmitted from the controller control unit 54 to the infrared communication unit 200 of the cradle 16, and the CPU 102 of the cradle 16 confirms the received current profile 90 based on the verification data 92. To do. When the received current profile 90 and verify data 92 are determined to be normal, the CPU 102 transmits a handshake signal 94 as a normal reception notification. The controller 14a also transmits a predetermined caution signal from the controller control unit 54 to the infrared communication unit 200 when the charge amount of the controller power source 52a is insufficient, and prompts the controller display 52 to replace the controller power source 52a. You may display.

  In step S6, after the handshake signal 94 is received by the cradle 16, the user 62 or the patient 36 is notified by displaying “setting complete” on the operation display unit 68, for example. If reception of the handshake signal 94 cannot be confirmed by the operation display unit 68, the process returns to step S5.

  Next, in step S <b> 7, the user 62 or the patient 36 removes the patch 12 and the controller 14 a from the cradle 16, removes a predetermined protective film from the patch 12, and attaches the patch 12 and the controller 14 a to the patient 36. (See S8, FIG. 11). Since the lower surface of the patch 12, that is, the contact surface with the patient 36 has an appropriate adhesive force, the patch 12 and the controller 14 a will not fall out of the patient 36.

  In step S9, the user 62 or the patient 36 turns on the administration control switch 46. As a result, the CPU 100 reads the current profile 90 from the internal memory 58 and energizes the connection hooks 42a and 42b from the driver 60 based on the current profile 90. As a result, an electrophoretic principle causes a current to flow from the donor reservoir 22, which is the positive electrode, to cross the stratum corneum of the skin of the patient 36, pass through the inside of the body from the stratum corneum, and flow to the return reservoir 24, which is the negative electrode. . Therefore, the drug 38 having a positive charge moves in the same manner as the current described above, but is absorbed into the body of the patient 36 at the stratum corneum layer. In contrast to the above-described current, anions such as chloride ions in the physiological saline 40 cross the stratum corneum of the patient 36 from the return reservoir 24 and then pass through the inside of the body from the stratum corneum. To the donor reservoir 22. In addition, the drug 38 is administered to the patient 36 at a time and administration rate based on the current profile 90.

  When administration is performed normally, the green light 48b blinks (step S10), and the user 62 or the patient 36 is notified. If the green light 48b does not blink, it is possible that an abnormality has occurred. If an abnormality has occurred, the red lamp 48a blinks rapidly (step S11). When the red lamp 48a blinks rapidly, the administration control switch 46 is once turned off (step S12), and the process returns to step S8. If neither the red light 48a nor the green light 48b blinks, the process returns to step S8. When the administration rate based on the current profile 90 is not satisfied, the controller control unit 54 performs control so as to follow the current profile 90. When the administration of the medicine 38 is normally completed, the administration control switch 46 is automatically turned off, and both the red light 48a and the green light 48b are turned off (step S13).

  When the same type of patch 12 is subsequently used after the administration of the medicine 38, the appropriate current profile 90 has already been read, so the cradle 16 is used again without reading the current profile 90. The patch 12 may be replaced and the drug 38 may be administered. However, in order to prevent the patch 12 from being mixed, it is possible to set so that the medicine 38 cannot be administered unless the cradle 16 is used.

  Next, as shown in FIG. 12, a transdermal drug administration system 10b according to a second embodiment will be described. In the transdermal drug administration system 10b according to the second embodiment, the same components as those in the transdermal drug administration system 10a are denoted by the same reference numerals, and detailed description thereof is omitted.

  The transdermal drug administration system 10b according to the second embodiment includes a patch 12, a controller 14b, and a cradle 17 as a basic configuration.

  As shown in FIGS. 12 and 13, the controller 14b includes a pair of connection hooks 42a and 42b, a power switch 44, an administration control switch 46, a red light 48a, a green light 48b, a controller communication window 50, a controller power supply 52b, A pair of charging hooks 80 and a controller control unit 54 that is an electric circuit of the controller 14 are configured. That is, the controller 14a has a configuration in which the controller power supply 52a is replaced with the controller power supply 52b and a charging hook 80 is added.

  The controller power source 52b has a power storage function, and may be a rechargeable secondary battery (for example, a lithium ion battery) or a capacitor. The controller power source 52b may be configured or sized so that the controller 14b can be carried. That's fine. As a result, the frequency of replacement of the controller power supply 52b is reduced, and maintenance is simplified.

  As shown in FIG. 13, the charging hook 80 is a hole disposed on the same surface as the controller communication window 50 in a size and a position that can be engaged with a charging pin 82 described later.

  As shown in FIG. 12, the cradle 17 includes a power cord 64, a power switch 66, an operation display section 68, a cradle communication window 70, a set mark 72, a cradle control section 74, and a pair of charging pins. 82 and a charge switch 84. That is, the charging pin 82 and the charging switch 84 are added to the cradle 16.

  As shown in FIG. 12, the charging pin 82 is protruded from the cradle wall 17 b in a size and position that can engage with the charging hook 80 with a slightly thicker tip. When the charging pin 82 is engaged with the charging hook 80, the controller power source 52 b can be charged by the power supplied from the cradle 17. Note that a contactless charging method in which power is supplied by electromagnetic induction between coils, for example, without connecting wires such as the charging hook 80 and the charging pin 82 may be used. Furthermore, the controller 14b may not be integrated with the patch 12 during charging.

  The charging switch 84 is provided on the side surface of the cradle body 17a, and has a function of charging the controller power source 52b in an on state and terminating charging in an off state. Note that it may have a function of automatically turning off when charging is completed. Alternatively, the current charging status may be transmitted from the controller communication unit 56 to the infrared communication unit 200 using infrared communication, and the charging status may be displayed on the operation display unit 68. For example, “charging” may be displayed during charging and, similarly, “charging completed” may be displayed at the end of charging. Regardless of whether the charging switch 84 is on or off, self-help charging may be performed based on the amount of power stored in the controller power supply 52b.

  The transdermal drug administration system 10b is basically configured as described above. Since the transdermal drug administration method according to the present embodiment to which the transdermal drug administration system 10b is applied is the same as the transdermal drug administration method to which the transdermal drug administration system 10a is applied, The description is omitted.

  Next, a transdermal drug administration system 10c according to a third embodiment will be described. Regarding the transdermal drug administration system 10c according to the third embodiment, the same components as those of the transdermal drug administration system 10a according to the first embodiment are denoted by the same reference numerals, and detailed description thereof will be given. Omitted.

  A transdermal drug administration system 10c according to the third embodiment includes a patch 12, a controller 14c, and a cradle 16 as a basic configuration. That is, the controller 14a is replaced with the controller 14c.

  As shown in FIG. 14, a plurality of files 152 are recorded as a database 150 in the internal memory 120 of the controller control unit 54 of the controller 14c. In each file 152, data such as drug type data 154 corresponding to the type of the patch 12, drug filling amount data 156, current profile 90, and search identification information 34 a for searching the file 152 with the identification information 34 is written in advance. It is. In this case, a predetermined selection unit based on the software function of the CPU 100 searches the search identification information 34 a corresponding to the identification information 34 received by the controller control unit 54, so that an appropriate file 152 is retrieved from the database 150 of the internal memory 120. Will be selected. Note that the file 152 is data with a small amount of information and can be written in the internal memory 120 in a sufficiently large amount.

  The transdermal drug administration system 10c is basically configured as described above. The transdermal drug administration method according to the present embodiment to which the transdermal drug administration system 10c is applied is shown in FIG. 15, and the transdermal drug administration to which the transdermal drug administration system 10a is applied. The description of the same steps as the method is omitted.

  In step S104 (corresponding to step S4 in the first embodiment), when the identification information 34 is received by the RF communication unit 110, the verification data 92 in a predetermined format is transmitted together with the identification information 34 read by the cradle 16 by infrared communication. The data is transmitted from the unit 200 to the controller control unit 54 of the controller 14c using infrared communication.

  In step S105 (corresponding to step S5 in the first embodiment), the CPU 100 retrieves the search identification information 34a corresponding to the identification information 34 received by the controller control unit 54 of the controller 14c, whereby the internal memory The file 152 recorded in the database 150 of 120 is selected, and the medicine type data 154, the medicine filling amount data 156, the current profile 90, and the like are confirmed and selected. When it is determined that the received identification information 34 and verify data 92 are normal, the CPU 100 sends a handshake signal 94 as a normal reception notification via the controller communication unit 56 together with the medicine type data 154 and the medicine filling amount data 156. Sent to cradle 16.

  In step S106 (corresponding to step S6 in the first embodiment), the medicine type data 154 and the medicine filling amount data 156 received by the infrared communication unit 200 of the cradle 16 are displayed on the operation display unit 68. As a result, the user 62 can easily confirm the medicine 38 to be filled in the patch 12, and can prevent the wrong kind of medicine 38 from being administered. Further, after the handshake signal 94 is received by the infrared communication unit 200, the user 62 or the patient 36 is notified by displaying “setting complete” on the operation display unit 68, for example. If the type or amount of the medicine 38 cannot be confirmed on the operation display unit 68, or if the reception of the handshake signal 94 cannot be confirmed on the operation display unit 68, the process returns to step S102.

  As described above, according to the transdermal drug administration systems 10a, 10b, and 10c according to the present embodiment, the controller 14a, 14b, or 14c includes the power storage unit, so that the patient during drug administration is restrained. There is no (but of course not tolerate intense exercise). In addition, since the current profile 90 corresponding to the patch 12 can be automatically set by the single controller 14a, 14b, or 14c, management and confirmation thereof are easy. The current supply by the current profile 90 can supply an appropriate current that changes with time. In addition, since the type of the patch 12 is determined by the cradle 16 or 17 and does not need to be performed by the controller 14a, 14b or 14c, the effect that the system can be miniaturized can be achieved. In addition, a large number of current profiles 90 are recorded in the internal memory 58 or 120, and there are many types of patches 12 that can be handled. The driver 60 in the controller 14a, 14b or 14c can freely convert the supply current in time by a digital high frequency on / off method such as a PWM method, and there is no circuit limitation on the current supply pattern. .

  As a modification, a barcode as identification information storage means may be used in the first communication method, that is, communication between the patch 12 and the cradle 16, 17. At this time, the identification information 34 is recorded on the patch 12 as a barcode, and is read by the cradle 16, 17 provided with a scanner using, for example, an LD (Laser Diode) as the first communication unit. Thereby, a cheaper system can be established. Further, since the communication position and means (visible light and infrared light) are different between the first communication method and the second communication method, stable communication can be performed without interference.

  As another modification, a two-dimensional code such as a QR code may be used as the identification information storage unit in the first communication method, that is, communication between the patch 12 and the cradle 16 or 17. At this time, the identification information 34 is recorded in the patch 12 as a two-dimensional code, and is read by the cradle 16, 17 equipped with a scanner using an LD, for example, as the first communication unit. Thereby, a cheaper system can be established. Further, since the communication position and means (visible light and infrared light) are different between the first communication method and the second communication method, stable communication can be performed without interference.

  The current profile 90 is basically recorded in advance at the manufacturing stage, but may be written by a doctor, nurse, pharmacist, public health nurse or the like depending on medical conditions and systems.

  The transdermal drug administration system according to the present invention is not limited to the above-described embodiment, but can of course take various configurations without departing from the gist of the present invention.

10a to 10c ... transdermal drug administration system 12 ... patch 14, 14a to 14c ... controller 16, 17 ... cradle 16a, 17a ... cradle body 16b, 17b ... cradle wall part 20 ... RF tag chip 20a ... passive RF tag 22 ... Donor reservoir 24 ... return reservoir 32 ... antenna 34 ... identification information 34a ... search identification information 36 ... patient 38 ... drugs 52a, 52b ... controller power supply 54 ... controller control unit 56 ... controller communication unit 58, 120 ... internal memory 62 ... use 74 ... Cradle control unit 80 ... Charging hook 82 ... Charging pin 90 ... Current profile 100, 102 ... CPU
110 ... RF communication unit 112 ... RF transmission / reception unit 114 ... RF antenna 150 ... database 154 ... drug type data 156 ... drug filling amount data 200 ... infrared communication unit

Claims (11)

A plurality of types of patches including identification information storage means that records identification information, as well as drugs in the electrode section,
A controller including a power storage unit connected to one of the patches and supplying power to the electrode unit;
A cradle in which the patch and the controller are set;
Have
The cradle has a storage unit in which a plurality of profiles including the administration rate and administration time of the drug according to the type of the patch are recorded,
A first communication unit that reads the identification information from the patch;
A selection unit that selects one of a plurality of profiles in the storage unit based on the identification information obtained from the first communication unit;
A second communication unit for supplying a profile selected by the selection unit to the controller;
With
The said controller changes the electric current from the said electrical storage part to the said electrode part based on the profile obtained from the said 2nd communication part, The transdermal drug administration system characterized by the above-mentioned. A plurality of types of patches including identification information storage means that records identification information, as well as drugs in the electrode section,
A controller including a power storage unit connected to one of the patches and supplying power to the electrode unit;
A cradle in which the patch and the controller are set;
Have
The cradle includes a first communication unit that reads the identification information from the patch;
A second communication unit that supplies identification information obtained from the first communication unit to the controller;
With
The controller includes a storage unit in which a plurality of profiles including the administration rate and administration time of the drug according to the type of the patch are recorded;
A selection unit that selects one from a plurality of profiles of the storage unit based on identification information obtained from the second communication unit;
A transdermal drug administration system, wherein the current from the power storage unit to the electrode unit is changed based on the profile selected by the selection unit. The transdermal drug administration system according to claim 1 or 2,
The first communication unit is a communication unit according to a predetermined first communication method,
The transdermal drug administration system, wherein the second communication unit is a communication unit using a second communication method different from the first communication method. The transdermal drug administration system according to claim 3 ,
The identification information storage means is an RF tag chip,
The first communication method is RF communication. The transdermal drug administration system according to claim 4,
The RF tag chip is a passive type transdermal drug administration system. The transdermal drug administration system according to any one of claims 3 to 5,
The transdermal drug administration system, wherein the second communication method is infrared communication. In the transdermal drug administration system according to any one of claims 1 to 6,
The cradle is capable of charging the power storage unit. According to claim 1 or 2 Symbol placement Transdermal Drug Delivery System,
The transdermal drug administration system, wherein the identification information storage means is a barcode. According to claim 1 or 2 Symbol placement Transdermal Drug Delivery System,
The percutaneous drug administration system, wherein the identification information storage means is a two-dimensional code. The transdermal drug administration system according to claim 8 or 9,
The transcutaneous drug administration system, wherein the first communication unit is a scanner. The transdermal drug administration system according to claim 1,
The percutaneous drug administration system, wherein the profile further includes an initial acceleration time for increasing a dose rate at the start of drug administration.

Images